On June 14, the Sixth Panel (Sexta Turma) of Brazil’s Superior Court of Justice’s (Superior Tribunal de Justiça, or STJ) issued a resolution permitting cultivation of hashish for medical functions. The STJ is chargeable for uniformizing the interpretation of Brazilian federal legislation throughout the nation, and serves because the court docket of ultimate enchantment for circumstances that don’t contain constitutional issues. While the STJ resolution applies solely to the three plaintiffs in the case at hand, it establishes a precedent that decrease courts can comply with.
Back in March 2021, in Cannabis for Brazilian Pets and Their Humans, we famous that Brazilian courts had been granting habeas corpus petitions made by residents in search of to develop their very own hashish for medical functions, including that it will be fascinating to see if the pattern resulted in judicial selections of broader utility. The STJ has now supplied a solution, and one which represents excellent news for medical hashish customers.
Brazil legalized the prescription of hashish merchandise for medical use in 2014, however an ongoing prohibition on cultivation beneath Brazil’s Drugs Law (Law 11.343/06) compelled shoppers to depend on costly imports. The three plaintiffs in the STJ resolution had authorization from the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância Sanitária, or Anvisa) to import cannabidiol (CBD), however excessive import prices compromised their entry to their remedy.
Explaining the STJ’s reasoning for safeguarding the plaintiffs in opposition to utility of the Drugs Law, Minister Sebastião Reis Júnior argued that the authorized remedy of hashish cultivation actions can’t be divorced from their goal. Where cultivation is a part of the pursuit of the fitting to well being, criminalization is unjustified. On this word, the Sixth Panel’s justices criticized the regulators’ failure to supply for authorized cultivation for medical and scientific functions. For Minister Rogerio Schietti Cruz, “this regulatory omission creates a segregation between sufferers who can afford remedy, importing cannabidiol-based medication, and people who can’t.”